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ABSTRACT 
In this paper is reported the “in vitro”release kinetic studies of antiepileptic drugs released from an inorganic, titanium 
oxide (TiO2)porous matrix. In order to determine the drug release mechanism, the experimental values were fitted to 
different mathematical models: zero-order, firs-order, Higuchi, Hixson-Crowel and Peppas. TiO2 was prepared by the sol-
gel method adding valproic acid (VPA) or phenytoine (DHP) during the titanium n-butoxide hydrolysis step. The drug-TiO2 
systems were observed by scanning electron microscopy. The “in vitro” release experiments were performed at laboratory 
scale following theUnited States Pharmacopeia (USP)standards.The obtained materials have a morphology of 
nanoparticle agglomerates. The particles have different sizes with some roughness and spherical shape. Peppas model 
suggests for both systems, that the release mechanism is controlled by two parallel processes. The firstone is by diffusion 
of the drug through the matrix and the second is related to a gradient of constant diffusion byingress of the solvent in the 
matrix. 
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1.INTRODUCTION  
Currently, the interest on the designing and preparation of drug delivery systemshas significantly increaseddue to their 
potential advantages that those may offer in comparison to conventional drug therapies[1-6]. At present, there are a large 
number of research papers devoted on the preparation of drug release system using nanotechnology [7-11].The 
highdemand is thanks to the possibility to reach efficient and safe levels required for the introduction of drugs; it is possible 
to including poorly soluble drugs and biomacromolecular drugs. The benefits ranging from the retention of the therapeutic 
activity of the drug, protection of the drug from chemicaland enzymatic degradation, control of drug release rate, to 
increasing the bioavailability, and reduction of toxicity, immunicity, and other biological side-effects. In different 
nanometric-forms (nanotubes, nanoparticles, nanospheres, etc.) polymeric and/or inorganic materials have been used for 
drug delivery applications[12-17]. Among the various inorganic materials, titanium dioxide, or titania (TiO2) has shown to 
be biocompatible [18, 19] and environment friendly. In addition, titania has a stable structure, is non-immunogenicity, is 
easy to prepare and has unique photoresponsive properties. Some biomedical applications of TiO2including 
phothosensitizer carrieron TPD, for DNA delivery,diagnostic imaging, and biosensors have been reported in literature[20–
22]. Mesoporous TiO2networks havealso been synthesized for encapsulation and release of antiepileptic drugmolecules 
[23], anticancer drug [24, 25] promoter of bone formation [26], antibiotics [27],  
anti-inflammatory [28], among others. 
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“In vitro” release studies allow us to know the rate drug through the matrix, then to determine the parameters that influence 
in the drug release mechanism allowing optimizing the studied formulation. It also is possible to adapting the release 
mechanism of a studied drug with respect to the commercial drug. Finally, it providesus similarinformation about release 
behaviorthat may take place in “in vivo” applications.   
The “in vitro” experimental values can be fitted to both simple and sophisticated mathematical models in order to make a 
theoretically study of the drug release mechanism. Most of the models that have been developed are based on solutions 
of the Fickian diffusion equation. The phenomenon of diffusion is intimately connected to the structure of the 
materialthrough which the diffusion takes place.Themechanisms of drug release offer a convenient way to 
categorizecontrolled release systems into: (i) diffusion-controlled; (ii) swelling controlled; and (iii) chemically controlled 
[29].There are severalmodels which describe the different drug release mechanism: 1) Zero-order modeldescribes the 
drug dissolution of several types of  modified release pharmaceutical dosage forms, as in the case of some transdermal 
systems, as well as matrix tablets with low soluble drugs in coated forms, osmotic systems [30, 31]. 2) First order modelis 
used to describe the drug dissolution in pharmaceutical dosage forms such as those containing water-soluble drugs in 
porous matrices [32].3) Higuchi modeldepicts the drug dissolution from several types of modified release pharmaceutical 
dosage forms, as in the case of some transdermal systems and matrix tablets with water soluble drugs [33]. 4) Hixson 
Crowell modelisapplied to pharmaceutical dosage form such as tablets, where the dissolution occurs in planes that are 
parallel to thedrug surface if the tablet dimensions diminish proportionally,in such a manner that the initial geometricalform 
keeps constant all the time[34]. 5) In the Korsmeyer-Peppas model, the value of “n” characterizes the release mechanism 
of drug as follow: if 𝑛 ≤ 0.45, the release mechanism follows Fickian diffusion; if 0.45 <𝑛< 0.89, the release occurs by non-
Fickian diffusion; and if 𝑛 = 1, it is a zero order process [35]. 
In the present work, valproic acid and phenytoin (Scheme 1)which are two antiepileptic drugs were stabilized into a titania 
network. The aim of this work is established the drug release mechanism with the purpose to obtain local drug release 
systems into the brain.  
According to the obtained results of the release profiles, it can be recommended the dose of drugs to be. 
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Scheme 1 Chemical structures of (a) Phenytoin (DPH) and (b) Valproic acid (VPA) 
2. EXPERIMENTAL 
2.1 Materials 
Ethanol (Vetec, 96%), titanium butoxideTi(OBut)4) (Aldrich, 98%),Valproic acid (Aldrich, 98 %), Phenytoin (Aldrich, 98%). 
2.2 Methods 
2.2.1 Samples preparation.   
The encapsulation of valproic acid (VPA) or phenytoin (DPH) within a hydroxylated titania matrix was achieved in a single 
step using the sol-gel procedure. In Table 1 are given the chemical precursor quantities and the molar rations used in the 
preparation of the TiO2-VPA and TiO2-DPH samples. TiO2 reference was prepared under the same experimental 
conditions as the titania-drug samples. 
The next procedure was carried out: the respective amount of VPA or DPH was dissolved in the adequate mixture of 
distillated water and ethanol, under stirring at room temperature. Then, titanium (IV) tetrabutoxide was added drop by drop 
to the drug solution in a lapse of 4 h.Thefinal mixture wasstirred at 25°Cuntil to complete theformation of the gel. Finally, 
the water and alcohol were removed with vacuum.Next the samples were dried at 30 °C for 8 h. 
Table 1. Quantities of drug and Alkoxide:water:ethanol molar rations used to prepare antiepileptic drug-titania samples. 
Samples Drug quantity 
(mg) 
Alkoxide: water: 
ethanolratio(mol) 
TiO2/DPH-50 50 1:16:8 
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TiO2/DPH-100 100 1:16:8 
TiO2/DPH-250 250 1:16:8 
TiO2/VPA-200 200 1:8:8 
TiO2/VPA-400 400 1:8:8 
TiO2/VPA-800 800 1:8:8 
2.2.2 Samples characterization. 
Scanning Electron Microscopy(SEM). Morphology was analyzed by scanning electron microscopy (SEM JEOL-5600 LV) 
at 20kV. Samples were coated with a layer of gold of approximately 20 nm using an EMS 550 sputter coating. 
2.2.3 “In vitro” drug release. 
“In vitro” releasesmeasurements were performed at laboratory scale, according to the USP XXXVstandards [36]. The 
samples were suspended in 150 ml of hydrochloric acid (HCl) 0.1 N/tribasic sodium phosphate (Na3HPO4) 2 M in a 
3:1volume ratio (pH 6.8). The dissolution medium was kept under stirring at 50 rpm. All the 
experimentalmeasurementswere carried out at 37°C ± 0,2
0
C. For VPA quantification an HPLC (SMARTLIN 2600 Konik 
with detector DAD) equipment with UV detector was used monitoring the signal at λ= 309. The DPH quantification was 
determinate by UV spectroscopy (UNICAM UV- 530). At determinedintervals of time an aliquot of 3 ml was removed from 
the release medium for spectroscopic measurement at λ=232 nm.After each measurement the aliquot was returned to the 
release medium.The experiments were made for duplicated. For each case a curve of calibration was previously built and 
it was used to quantify the released drug. 
2.2.4 Encapsulation efficiency (E.E%) determination.  
The amount of valproic acid (VPA) or phenytoin (DPH)loaded in the prepared samples wasdirectly estimated by 
dissolution of 5mg of each sample in 10 ml of phosphate-buffered saline (PBS) 0.1M at room temperature. After the 
dissolution the VPA amount release was determined by HPLC while the DPH amount was determined by ultraviolet 
spectroscopy.The encapsulation efficiency (E.E) was calculated using the following equation. 
100(%).
T
R
x
m
m
EE                 (1) 
 
mR= mass of each drug released from titana and mT= theoreticaldrug content. 
 
2.2.5 Yield (Y%.).  
The nanostructured materials (NM) yield determination (Y%) was calculated according to the following equation: 
100(%)
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p
x
mm
m
Y

                    (2) 
mp: is the total mass of the obtained drug-titania materials. 
m.:  is the mass of VPA orDPH used in each synthesis 
m.Ref:is the massof titania without drug (a titania reference)  
2.2.6 Data analysis 
To analyze the “in vitro”release data various kinetic models were used to determine the release mechanism. The zero 
order rate equation (3) describes the systems where the drug release rate is independent of its concentration [37]. The 
first order equation (4) describes the release drug from systems where release rate is concentration dependent [38]. 
Higuchi [39] described the release of drugs from insoluble matrix as a square root of time dependent process based on 
Fickian diffusion equation (5). The Hixson-Crowell cube root law equation (6) describes the release from systems where 
there is a change in surface area and diameter of particles [40]. 
C = kot(3) 
 
Where, K0 is zero-order rate constant expressed in units of concentration/time and t is the time. 
LogC = LogCo−kt/ 2.303   (4) 
Where, C0 is the initial concentration of drug and K is first order constant. 
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Q = Kt
1/ 2
            (5) 
 
Where, K is the constant reflecting the design variables of the system. 
 
Q0
1/3
– Qt
1/3
 = KHC t    (6) 
 
Where, Qt is the amount of drug released at a time t, Q0 is the initial amount of the drug in tablet and KHC is the rate 
constant for Hixson-Crowell rate equation. 
The following plots were made: cumulative % drug release vs. time (zero order kinetic model); log cumulative of % drug 
remaining vs. time (first order kinetic model); cumulative % drug release vs. square root of time (Higuchi model) log 
cumulative % drug release vs. log time (Korsmeyer model) and cube root of drug % remaining in matrix vs. time (Hixson-
Crowell cube root law). 
2.2.7 Drug release mechanisms. 
Korsmeyer [41, 42] derived a simple relationship which described drug release from a polymeric system Eq. (7). To find 
out the mechanism of drug release, first 60% drug release data was fitted in Korsmeyer–Peppas model: 
Mt/M∞= Kt
n
(7) 
Where Mt / M∞ isfraction of drug released at time t, K is the rate constant and n is the release exponent. The n value is 
used to characterize different release mechanisms (see Table 2). 
 
Table 2. Diffusion exponent and solute release mechanism. 
 
Diffusion exponent 
(n) 
 
Overall solute diffusionmechanism 
0.45 Fickian diffusion 
0.45 < n < 0.89 Anomalous (non-Fickian) diffusion 
0.89 Case-II transport 
n > 0.89 Super case-II transport 
 
3. RESULTS AND DISCUSSION  
In a previous paper was reported the physical-chemistry characterization of all materials presented in this work [43].Table 
3 summarizes the encapsulation efficiency and the yield of particles for all samples. From the table it is possible to 
determinethat there is an effect of the kind of the drug on the gelationtime. When VPA was encapsulated, the gelation time 
increased almost doubling that for VPA encapsulation. However, the drug amount did not have effect on the gelation time.  
In the case of DPH there is a maximum of Y% with sample containing 100 mg. A similar behavior was observed in the EE 
values. For the case of VPA encapsulation both the Y% and the EE % decrease as the VPA amount was increased.  In 
this case low amount of drug can be dispersed in the complete network of titania. Larger amount of drug can block the 
pore mouth, this is not happen in the case of small ones. 
Table 3. Yield and encapsulation efficiency % for all samples. Y (Yield) and E.E (Encapsulation 
efficiency). 
 
Sample Y  
(%) 
EE  
(%) 
Gelation  time  
(h) 
TiO2/DPH-50 82±0.5 32±0.5 35 
TiO2/DPH-100 92±0.5 66±0.3 35 
TiO2/DPH-250 72±0.5 42±0.5 35 
TiO2/VPA-200 96±0.4 78±0.2 60 
TiO2/VPA-400 86±0.5 62±0.5 60 
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Figure 2 shows the SEM images for the different Drug-TiO2 systems.Aggregates are observed and are formed by 
spheroidal particles, as a role the surface presents small roughness. The agglomerates have variable sizes. The materials 
have a size of about 400- 500 nm. 
 
 
(a) (b) (c)
(d) (e) (f)
 
 
Figure 2. Scanning electron micrographs (SEM) of  (a) TiO2/VPA-200, )b) TiO2/VPA-400, (c) TiO2/VPA-800, (d) TiO2/ 
DPH-50, (e) TiO2/ DPH-100,(d) TiO2/ DPH-250. 
3.1 Kinetics studies 
Release profiles for DPH and VPA are shown in figures 3 and 4 respectively. Both figures present at least two drug 
release stages. The first one is observed between 0-12 hours, and the second between 12 and 22 hours. 
There is a direct effect of the E.E on the released drug amount. However samples prepared with the highest drug content 
did not present the highest release profile.However, the profiles obtained did not present burst, indicating an effective drug 
encapsulation into the TiO2 matrix.  
TiO2/VPA-800 72±0.5 55±0.5 60 
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Figure 3. Release profiles of the nanostructured materials of TiO2/DPH related to E.E. 
 
Figure 4. Release profiles of the nanostructured materials of TiO2/VPA related to E.E. 
Considering proper mechanisms such as zero order, first order, Higuchi and Hixson-Crowell cube-root model, was 
observed that the first order and the Hixson Crowell mechanism can be completely ruled out (Table 4) in comparison with 
the others. However, the observed fittingsobtained for the other mechanisms disagreement too. Data did not permit to 
select among of them. Another option was fitted the experimental data with the empirical Peppas equation to obtain the 
"n"exponent of the variable time. The "n" obtained valueswere around 0.13-0.22for the DHP and 0.30 for the VPA 
respectively. Theseresultsareextremely low and the correlation coefficients are not good. For these systems the "n" 
valuenot within the interval between 0.5 and 1.  
Considering the results shown in Table 4 and the fact that releasing curves seem to present two stages was necessary to 
analysecombined mechanisms are operating. With the purpose to analyse this behaviour, the experimental release data 
were dividedin two parts, the first, between 0 and 10 hours and the second between 12 and 22 hours. It is to be noted that 
when was applied the Peppas approximation to each complete profile data,the “n” valuefor each onewasextremely low, in 
fact much lower than 0.4. 
Table 4. Correlation Coefficients (r) for linear relationship of the proposed combined Kinetics of (0-22 h) of TiO2/DPH and 
TiO2/VPA. 
Samples Zero 
Order 
 
r
2
 
First 
Order 
 
r
2
 
Higuchi 
 
r
2
 
Hixson 
Crowell 
 
r
2
 
Korsmeyer-
Peppa 
  
“n” 
TiO2/DPH-50 0.9270 0.9311 0.9278 0.8449 0.15 
TiO2/DPH-100 0.9806 0.9619 0.9409 0.8770 0.22 
TiO2/DPH-250 0.9568 0.9468 0.9060 0.8428 0.13 
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TiO2/VPA-200 0.9666 0.9731 0.9065 0.8393 0.30 
TiO2/VPA-400 0.9822 0.9507 0.9320 0.8240 0.38 
TiO2/VPA-800 0.9497 0.9352 0.9197 0.8517 0.30 
 
This data processing did not offer a clear definition of what mechanism is ruling the release process, however, the Peppas 
empirical equationapplied to each time interval (Table 5) gave the interesting following result: 
Table 5. “n” obtained values from the experimental data for DPH and VPA.  
 
Samples            “n”  value 
 (0-10) h (12-22) h 
TiO2/DPH-50 0.31 0.41 
TiO2/DPH-100 0.40 0.44 
TiO2/DPH-250 0.43 0.42 
TiO2/VPA-200 0.40 0.49 
TiO2/VPA-400 0.44 0.46 
TiO2/VPA-800 0.49 0.43 
 
In both VPAand DPH systems, the whole process is not ruled by only one mechanism as is suggesting by the release 
profiles. However for the DPH system“n” is approximately constant. The difference between the behaviour of DPH and 
VPA consists that in the latter the beginning of the process is different to the first one. According to the release profiles the 
VPA systems seem to turn to a well-defined zero order mechanism and not to a fickeanmechanism.  
The very low values of “n” indicate   that an extra factor is competing, such as has been observed in hydrogels [44] where 
the geometry of the device is changing. However, this is not the case for the TiO2which possesses a well-defined stiff 
spatial structure. TiO2 is a porous and hydrophilic material that can be embedded by the water, thus the drug can be taken 
out by the solvent where controlled diffusion operates at the beginning but later the gradient becomes constant and 
system tend to zero order.  It would be an explanation of experimental facts.  
4. CONCLUSIONS 
The release mechanism for both drug is not govern by only one mechanism. It was observed an initial fickean mechanism 
with subsequent deviation of the mechanism, indicating that other extra factor competed with such fickean mechanism. As 
titania is a porous and hydrophobic material it can absorbed water to extract the drug from the matrix. Peppas model 
suggests for both cases, the release mechanism is controlled by two parallel processes. The first is by diffusion of the drug 
through the matrix and the second is related to a gradient of constant diffusion by ingress of the solvent in the matrix. The 
best drug release profiles were for the TiO2/DPH-100 (E.E, 66 %) and TiO2/VPA-200 mg (E.E, 78 %) samples. TiO2/DPH 
(100 mg) and TiO2/VPA (200 mg) presented the best release profiles, which may have high potentials for in vivo 
applications.  
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